Revenue Breakdown
Composition ()
No data
Revenue Streams
Cumberland Pharmaceuticals Inc (CPIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sancuso, accounting for 28.8% of total sales, equivalent to $3.12M. Other significant revenue streams include Kristalose and Vibativ. Understanding this composition is critical for investors evaluating how CPIX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Cumberland Pharmaceuticals Inc maintains a gross margin of 75.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.70%, while the net margin is -23.50%. These profitability ratios, combined with a Return on Equity (ROE) of -13.08%, provide a clear picture of how effectively CPIX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CPIX competes directly with industry leaders such as GRCE and ACRV. With a market capitalization of $58.48M, it holds a leading position in the sector. When comparing efficiency, CPIX's gross margin of 75.90% stands against GRCE's N/A and ACRV's N/A. Such benchmarking helps identify whether Cumberland Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
